PE
GMAB icon

Point72 Europe’s Genmab GMAB Stock Holding History

Point72 Europe’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$3.31M Sell
107,864
-363,836
-77% -$8.87M 0.16% 105
2025
Q2 		$9.75M Buy
+471,700
New +$9.68M 0.38% 71

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Europe's GMAB Position: Q3 2025 in Review

Point72 Europe reduced its Genmab (GMAB) stake by 77% in Q3 2025, selling an estimated $8.87M and leaving 107,864 shares worth $3.31M. The position accounts for 0.16% of the portfolio, ranked #105.

Point72 Europe first reported a position in GMAB in Q2 2025 and has held it in 2 quarters since. The position peaked at $9.75M in Q2 2025. 252 funds tracked by Wall St. Rank hold GMAB as of Q3 2025.

  • Point72 Europe held 107,864 shares of Genmab worth $3.31M as of Q3 2025.
  • Point72 Europe sold 363,836 Genmab shares in Q3 2025, an estimated $8.87M.
  • Genmab made up 0.16% of Point72 Europe's portfolio in Q3 2025, its #105 holding.
  • Point72 Europe first reported a position in Genmab in Q2 2025 and has held it in 2 quarters since.
  • Point72 Europe's Genmab position peaked at $9.75M in Q2 2025.
  • 252 funds tracked by Wall St. Rank held Genmab as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.